Company / Cash & Equivalents
ACCENDRA HEALTH INC/VA/ Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$282.0M
FY2025
5-year range
$27.6M / $282.0M
FY2021-FY2025
Trend
+922.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +923% YoY in FY2025, a notable deviation from the 9-year average annual change of +113%.
Based on SEC 10-K filings.
$282M in FY2025 with a 5-year CAGR of +27.7%.
Improved from $243M to $282M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +59.5%
- 5-Year CAGR
- +27.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +27.7%, indicating consistent growth.
- In FY2025, cash & equivalents increased 922.7% year-over-year.
- Lowest cash & equivalents in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $282.0M | +922.7% |
| FY2024 | $27.6M | -88.7% |
| FY2023 | $243.0M | +249.9% |
| FY2022 | $69.5M | +24.7% |
| FY2021 | $55.7M | -32.9% |
| FY2020 | $83.1M | +23.9% |
| FY2019 | $67.0M | +1.1% |
| FY2018 | $66.3M | -36.6% |
| FY2017 | $104.5M | -43.7% |
| FY2016 | $185.5M | +15.2% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026